专家论坛
肝门部胆管癌的术前评估和术中导航研究进展
中华消化外科杂志, 2024,23(7) : 906-911. DOI: 10.3760/cma.j.cn115610-20240612-00291
摘要

肝门部胆管癌严重危害国人健康,在我国发病率和病死率均呈上升趋势。根治性手术切除是肝门部胆管癌唯一可能治愈的有效手段,但由于患者确诊时多为晚期,且肝门部解剖结构复杂、高位胆管肿瘤无法精准定位,根治性手术切除率低,致使我国肝门部胆管癌患者的远期生存率远低于国际领先水平。随着高精度影像检查方法和内镜下活组织检查的广泛开展,现已能在术前精确评估肝门部胆管癌的侵袭范围,然而术中高位胆管离断点的确定仍然只能依赖术者的经验,根据肝门部胆管与血管的解剖位置关系以及触诊的胆管软硬度来判断。临床迫切需要术中影像学辅助设备对肝门部胆管癌的侵袭范围进行实时成像,并精准引导胆管离断,从而提高根治性切除率,减少术后并发症发生率,进而提高肝门部胆管癌的远期生存率。笔者总结肝门部胆管癌的术前规划方法及术中导航技术的现状,并对胆管腔内超声检查在术中实时引导胆管离断的国际首次应用实例作出分析,旨在为术中导航技术的发展提出展望。

引用本文: 王宏光, 罗漫. 肝门部胆管癌的术前评估和术中导航研究进展 [J] . 中华消化外科杂志, 2024, 23(7) : 906-911. DOI: 10.3760/cma.j.cn115610-20240612-00291.
参考文献导出:   Endnote    NoteExpress    RefWorks    NoteFirst    医学文献王
扫  描  看  全  文

正文
作者信息
基金 0  关键词  0
English Abstract
评论
阅读 0  评论  0
相关资源
引用 | 论文 | 视频

版权归中华医学会所有。

未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。

除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

肝门部胆管癌是一种源自胆管上皮的高度异质性恶性肿瘤1。由于其早期缺乏特征性临床表现,大多数患者在确诊时已为不可切除的晚期,预后极差,病死率逐年上升。根治性手术切除是唯一可延长患者长期生存时间的方法。术前精确评估肝门部胆管癌的侵袭范围,术中确定高位胆管离断点位置,对影响肿瘤复发与患者长期生存有重要作用。依赖于影像学引导的手术增强了术中肿瘤边界和无瘤边界的精确定位。近年来,内窥镜技术和术中超声检查技术的发展为肝门部胆管癌手术导航提供了新契机。笔者总结肝门部胆管癌的术前规划方法及术中导航技术的现状,并对胆管腔内超声检查在术中实时引导胆管离断的国际首次应用实例作出分析,旨在为术中导航技术的发展提出展望。

一、肝门部胆管癌的术前评估

肝门部胆管癌的最佳治疗方案是根治性手术切除(R0切除),但R0切除率仍有待提高2, 3。术前评估肿瘤的轴向浸润和侧方浸润范围对于制订手术计划至关重要,胆道狭窄的延伸情况可提供肿瘤沿胆管树轴向浸润的信息,从而确定相应的分期;对肿瘤侧方浸润范围的评估主要根据肝动脉、门静脉、肝实质等受累情况4。影像学方法可为术前手术规划提供重要信息。

(一)常规影像学技术的应用
1.多排螺旋CT、三维重建和直接胆管造影

肝门部胆管癌侧方浸润范围、软组织浸润及血管包绕情况依赖于多排螺旋CT检查,其对于可切除性评估的准确率为74.5%~94.4%5。用三维重建的方法处理多排螺旋CT扫描检查所得数据,可用于直接浸润及肝转移、淋巴结转移、周围神经侵犯的诊断6。伴有梗阻性黄疸的肝门部胆管癌,首先进行多排螺旋CT检查,根据肿瘤位置行右侧肝切除或左侧肝切除术,再通过经皮经肝胆管引流术或者内镜鼻胆管引流术对拟保留侧的胆管进行引流,并利用引流管进行直接胆管造影检查。经皮经肝胆管引流术和内镜鼻胆管引流术可降低胆红素,改善剩余肝脏的储备功能,纠正严重营养不良和凝血异常7。胆道梗阻导致高胆红素血症的患者,术前应评估肝储备功能及剩余肝体积能否耐受联合大范围肝切除。功能性剩余肝体积可通过CT检查及三维重建软件进行测量,应保留≥40%的正常肝实质,通常以引流后TBil降低速度进行评估。

2.MRI和MRCP

肝门部胆管由于解剖关系复杂常需要个性化地选择多种成像方法,通常通过MRCP或直接胆管造影检查进行评估。先参照MRCP检查结果显示的胆管树形态进行总体判断,根据CT和MRI层析成像检查结果显示的胆管壁增厚和增强征象进一步分析和判断肿瘤与正常胆管组织之间的边界。MRI联合MRCP检查进行术前分期评估的准确性与多排螺旋CT联合直接胆管造影检查的准确性相似,但前者的优势在于可以避免侵入性操作和造影剂的使用8。经皮经肝胆管造影术和ERCP可作为MRCP的替代方法,用于显示胆管癌的浸润程度。

3.PET/CT

对于CT及MRI等检查不能明确的病灶建议行PET/CT检查。其在实体瘤中可用于确定区域淋巴结转移、腹膜转移或远处转移9。对于进展期胆道恶性肿瘤患者,PET/CT检查有助于发现最大径≤1 cm的转移病灶和转移淋巴结1018氟-氟代脱氧葡萄糖PET检查对早期体积较小肿瘤不易检出,合并胆道感染可能存在假阳性的结果,且对浸润生长的肿瘤类型阳性率有限。PET/CT检查难以实现胆管内肿瘤浸润范围界定以指导手术方案的制订11

(二)内镜检查技术在术前评估的应用

由于肝门部胆管癌存在黏膜下浸润及黏膜层扩展,故依据影像学检查精确判断胆管轴向浸润范围常存在困难。内镜下胆管上皮多点采样活组织病理学检查并结合胆道三维重建影像定位,有助于提高对肿瘤轴向扩展程度判断的准确性。

1.经皮经肝胆道镜

经皮经肝胆道镜检查可用于胆管狭窄的诊断与治疗、准确诊断胆管癌。经皮经肝胆道镜检查可详细观察胆管内腔和直视下行黏膜活组织检查,对诊断胆管癌黏膜内进展范围、确认胆管切断位置有重要作用12。对于狭窄的下游侧在胆道造影检查时不显影,经皮经肝胆道镜检查时可用胆道镜抵在狭窄中心,经导管扩张,行下游侧胆管黏膜活组织检查。

2.EUS与细针吸取

EUS可评估胆囊及胆管病灶的局部侵犯情况、肝门区淋巴结和血管侵犯情况13。其与细针吸取取样相结合,适用于非侵入性技术无法确诊的患者,总体特异度为92%~100%14。EUS联合细针吸取检查可明确肿瘤位置、判断管壁的侵犯深度,并对疑似淋巴结进行活组织检查。Malikowski等15证实EUS联合细针吸取检查可有效识别不同亚型胆道肿瘤患者的恶性淋巴结。由于抽吸针穿过十二指肠球部和腹腔取样会增加肿瘤扩散风险,因此,EUS仅用于无法进行根治性手术的患者,指导合适的一线治疗方案。

3.经口胆道镜

经口胆道镜可用于胆管癌轴向进展的诊断,多联合胆管腔内超声检查(intraductal ultrasonography,IDUS)行经乳头胆管活组织检查,通常在内镜下十二指肠乳头括约肌切开术或球囊扩张处理乳头部后将胆道镜导入胆管,需通过母镜(ERCP十二指肠镜)将子镜导入胆管,而经乳头插入胆道镜并越过狭窄部位的操作较为困难,目前临床不常用,但随着技术改良,管径更细的经口胆道镜应用将会更加广泛16。Bukhari等17曾报道联合使用经口和经皮经肝胆道镜直接引导下穿刺,可以精细操作穿刺针,降低出血和穿孔的风险。经口胆道镜的缺点在于检查需切开乳头进行,并且对于肿瘤上游侧进展程度诊断不充分。经口胆道镜包括直接胆道镜和间接胆道镜技术,目前临床上已出现多个经口胆道镜直视系统,其中常见的是直接经口胆道内镜、胆道子母镜系统、eyeMax洞察胆胰成像系统、SpyGlass数字单人操作胆道镜系统等18。Pereira等19报道使用SpyGlass DS对胆道狭窄患者进行评估并在直视下SpyBite活组织检查,诊断准确率为95.1%,灵敏度为100%、特异度为89.5%,该设备应用于肝门部胆管癌的诊断具有一定价值。

随着内窥镜技术的不断创新,SpyGlass DS数字单人操作胆道镜系统(Spy Glass DSOC)的问世,为肝门部胆管癌的术前肿瘤浸润范围边界划定提供了胆道成像、直视下活组织检查的技术选择,有利于术前肿瘤分型与手术方案的制订。近年来,内镜下活组织检查技术逐步提高,可在术前准确提供肿瘤病理学信息20。值得注意的是,Kurihara等21的1例病例报道SpyGlass成像质量低于视频胆管造影;在胆管内,由于SpyGlass的聚焦距离短,光量和分辨率有限,许多碎片和浓缩胆汁的存在影响了良好的观察效果。Chiang等22报道SpyGlass胆道镜可用于精确定位肝门部胆管癌,在手术前为外科医师提供更多信息。SpyGlass胆道镜检查实现了胆总管和胆道的可视化,可提供高分辨率的胆管图像,有望在肿瘤精确定位方面发挥作用22。然而,由于肿瘤阻塞胆管,SpyGlass胆道镜检查难以在手术中进行,除非术前先扩张狭窄部位。因此,该技术还需进一步改进,但SpyGlass系统具有评估胆管肿瘤浸润范围的潜力。

二、肝门部胆管癌的术中导航
(一)术中超声检查

腹部超声检查用于确认可疑的胆管梗阻,并确定狭窄的位置和程度。超声检查在局部进展程度的诊断上,可显示肝内胆管根部以了解肿瘤轴向进展程度,显示肝门部肿瘤并了解对动脉、门静脉和肝实质侧方浸润程度23。术中超声检查利用高频探头和直接接触扫描的两大优势,可以近距离观察肝内外胆管系统的形态以及与周围组织的关系,也可在术中判断有无肝转移、脉管侵犯以及淋巴结转移,进而确定肿瘤的可切除性,以及对肝门部胆管癌进行术中分期24, 25。术中超声检查可根据肝内胆管扩张与狭窄部位初步判断胆管离断点并以钛夹或钳夹作为标记26

由于劈开肝脏后肝门部胆管已完全显露,气体干扰和难于耦合使得术中探头,无论是经过肝脏还是直接放置于胆管表面,都不能清晰显示胆管壁各层结构,因此,开腹术中超声检查只能进行粗略导航。示例1:患者男,63岁,发现皮肤、巩膜黄染2周入院,术前MRI检查结果提示肝门部胆管占位并肝右叶占位。有糖尿病史。行肝动脉受累肝门部胆管癌扩大根治术,术中切除右半肝及肝外胆道,行门静脉及肝动脉重建。63岁男性患者术前影像学检查结果及开腹术中超声检查结果见图1

点击查看大图
图1
63岁男性患者术前影像学检查结果及开腹术中超声检查结果 1A:术前磁共振成像增强检查结果提示肝门部肿瘤占位伴胆管扩张(↓);1B:术中超声检查在肝门部胆管的解剖结构显示左肝管扩张(↓),左肝管拟切断处钛夹(↑);1C:肝门部胆管合并右半肝切除后显示肿瘤轴向浸润范围;1D:劈肝后暴露肝门部复杂位置关系与胆管分支显示肝中静脉(↑),钛夹标记左肝管拟切断点(➝);1E:肝门部血管复杂位置关系显露与胆管断端位置显示;1F:肝门部胆管切除后显示侧方浸润范围
Figure 1
Preoperative imaging examination results and intraoperative ultrasound examination results of a 63-year-old male patient 1A: Preoperative enhanced magnetic resonance imaging examination results indicate a tumor mass in the hepatic hilum with bile duct dilation (↓); 1B: Intraoperative ultrasound examination shows the anatomical structure of the bile duct in the hilum of the liver, with dilated left hepatic duct (↓) and titanium clip (↑) at the site where the left hepatic duct is to be cut off; 1C: After resection of the right half of the liver and hilar bile duct, the axial infiltration range of the tumor is displayed; 1D: After liver splitting, the complex positional relationship of the hepatic hilum and bile duct branches are exposed, displaying the middle hepatic vein (↑), and the titanium clip marks the intended cut-off point of the left hepatic duct (➝); 1E: Revealing the complex positional relationship of blood vessels in the hepatic hilum and displaying the position of bile duct rupture; 1F: After resection of the hilar bile duct, lateral infiltration range is displayed
点击查看大图
图1
63岁男性患者术前影像学检查结果及开腹术中超声检查结果 1A:术前磁共振成像增强检查结果提示肝门部肿瘤占位伴胆管扩张(↓);1B:术中超声检查在肝门部胆管的解剖结构显示左肝管扩张(↓),左肝管拟切断处钛夹(↑);1C:肝门部胆管合并右半肝切除后显示肿瘤轴向浸润范围;1D:劈肝后暴露肝门部复杂位置关系与胆管分支显示肝中静脉(↑),钛夹标记左肝管拟切断点(➝);1E:肝门部血管复杂位置关系显露与胆管断端位置显示;1F:肝门部胆管切除后显示侧方浸润范围
Figure 1
Preoperative imaging examination results and intraoperative ultrasound examination results of a 63-year-old male patient 1A: Preoperative enhanced magnetic resonance imaging examination results indicate a tumor mass in the hepatic hilum with bile duct dilation (↓); 1B: Intraoperative ultrasound examination shows the anatomical structure of the bile duct in the hilum of the liver, with dilated left hepatic duct (↓) and titanium clip (↑) at the site where the left hepatic duct is to be cut off; 1C: After resection of the right half of the liver and hilar bile duct, the axial infiltration range of the tumor is displayed; 1D: After liver splitting, the complex positional relationship of the hepatic hilum and bile duct branches are exposed, displaying the middle hepatic vein (↑), and the titanium clip marks the intended cut-off point of the left hepatic duct (➝); 1E: Revealing the complex positional relationship of blood vessels in the hepatic hilum and displaying the position of bile duct rupture; 1F: After resection of the hilar bile duct, lateral infiltration range is displayed
(二)IDUS检查

术前通过SpyGlass DS胆道镜直视化技术对肿瘤的侵袭边界划定及活组织检查后,通常会进行IDUS以确定肿瘤的侵犯范围,IDUS检查以微型超声探头经十二指肠侧插入胆道分支进行胆总管扫查,可清晰显示胆管和胰管腔内、管壁及其三维图像,并诊断黏膜和黏膜下的延伸范围27, 28, 29。IDUS检查在判断胆道狭窄的良、恶性和诊断胆管癌方面具有较高的准确性。狭窄段的IDUS图像具有沿导管周围组织浸润性病变、胆管壁不规则增厚和外回声壁层中断的特征30。根据IDUS检查结果,并结合胆管活组织检查,可确定浅表肿瘤扩展程度。

IDUS检查术前可帮助术者判断肿瘤的扩展程度,从而制订手术方案,但尚未有其在术中实时引导的病例报道。笔者团队已在国际上首次将IDUS检查应用于肝门部胆管癌术中引导胆管离断点,并已成功完成6例。示例1:患者女,82岁,发现胆管占位1周入院,有高血压、糖尿病史。术前MRI检查提示肝左叶近肝门部肿瘤。行肝动脉受累肝门部胆管癌扩大根治术,术中切除左三肝,肝右动脉受累切除重建。患者术前影像检查结果及术中IDUS检查图像显示见图2

点击查看大图
图2
82岁女性患者术前影像检查结果及术中IDUS检查情况 2A:磁共振成像检查示肝内胆管癌累及肝门部胆管并侵犯门静脉汇合部及肝右动脉;2B:劈开肝脏后经胆总管断端置入胆管腔内超声检查探头(➝)于右肝管内;2C:IDUS检查可见右肝内扩张的正常胆管(B1,B2,B3)以及PV、HA;2D:IDUS检查显示夹闭的右肝段胆管(B1)以及镊子回声(←);2E:IDUS检查引导右侧胆管断端(B5,B6,B7,B8);2F:门静脉右支及肝右动脉切除重建[肝右动脉吻合口(➝),门静脉右支吻合口(←)];2G:右肝4支段胆管成型后胆肠吻合(➝)
Figure 2
Preoperative imaging examination results and intraoperative intraductal ultrasonography (IDUS) results of a 82-year-old female patient 2A: Intrahepatic cholangiocarcinoma involving the bile ducts in the hepatic hilum and invading the portal vein confluence and right hepatic artery; 2B: After liver splitting, an IDUS probe (➝) is inserted into the right hepatic bile duct through the broken end of the common bile duct; 2C: IDUS results show normal dilated bile ducts (B1, B2, B3) as well as the portal vein and hepatic artery in the right liver; 2D: IDUS results show clamped right segment bile duct (B1) and forceps echo (←); 2E: IDUS guiding right bile duct stump (B5, B6, B7, B8); 2F: Right portal vein and right hepatic artery resection and reconstruction [right hepatic artery anastomosis (➝), right portal vein anastomosis (←)]; 2G: After formation of the 4 segments of right liver bile duct, the bile duct is anastomosed with the intestine (➝)
点击查看大图

注:IDUS为胆管腔内超声;RHD为右肝管;PV为门静脉;HA为肝动脉;B1为IDUS探头所在右肝段胆管;B2、B3为正常右肝段胆管;B5为肝Ⅴ段胆管;B6、B7为肝Ⅵ、Ⅶ段胆管;B8为肝Ⅷ段胆管

图2
82岁女性患者术前影像检查结果及术中IDUS检查情况 2A:磁共振成像检查示肝内胆管癌累及肝门部胆管并侵犯门静脉汇合部及肝右动脉;2B:劈开肝脏后经胆总管断端置入胆管腔内超声检查探头(➝)于右肝管内;2C:IDUS检查可见右肝内扩张的正常胆管(B1,B2,B3)以及PV、HA;2D:IDUS检查显示夹闭的右肝段胆管(B1)以及镊子回声(←);2E:IDUS检查引导右侧胆管断端(B5,B6,B7,B8);2F:门静脉右支及肝右动脉切除重建[肝右动脉吻合口(➝),门静脉右支吻合口(←)];2G:右肝4支段胆管成型后胆肠吻合(➝)
Figure 2
Preoperative imaging examination results and intraoperative intraductal ultrasonography (IDUS) results of a 82-year-old female patient 2A: Intrahepatic cholangiocarcinoma involving the bile ducts in the hepatic hilum and invading the portal vein confluence and right hepatic artery; 2B: After liver splitting, an IDUS probe (➝) is inserted into the right hepatic bile duct through the broken end of the common bile duct; 2C: IDUS results show normal dilated bile ducts (B1, B2, B3) as well as the portal vein and hepatic artery in the right liver; 2D: IDUS results show clamped right segment bile duct (B1) and forceps echo (←); 2E: IDUS guiding right bile duct stump (B5, B6, B7, B8); 2F: Right portal vein and right hepatic artery resection and reconstruction [right hepatic artery anastomosis (➝), right portal vein anastomosis (←)]; 2G: After formation of the 4 segments of right liver bile duct, the bile duct is anastomosed with the intestine (➝)
三、结语

随着影像学技术的飞速发展,术前手术规划已经逐渐完善,现阶段术中导航技术的革新已经逐渐成为肝门部胆管癌手术的焦点。术中超声检查技术对于肝门部胆管癌肝内转移病灶的鉴别与胆管解剖结构的分辨有巨大价值,而笔者在术中进行胆管腔内超声的首次应用,为我们提示了该技术新的发展潜力,若进一步提升IDUS检查应用的场景与精准度,有望在肝门部胆管癌精准手术导航中取得突破性进展。

引用本文:

王宏光, 罗漫. 肝门部胆管癌的术前评估和术中导航研究进展[J]. 中华消化外科杂志, 2024, 23(7): 906-911. DOI: 10.3760/cma.j.cn115610-20240612-00291.

利益冲突
利益冲突

所有作者均声明不存在利益冲突

参考文献
[1]
BrindleyPJ, BachiniM, IlyasSI, et al. Cholangiocarcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):65. DOI: 10.1038/s41572-021-00300-2.
[2]
BanalesJM, CardinaleV, CarpinoG, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(5):261-280. DOI: 10.1038/nrgastro.2016.51.
[3]
殷晓煜. 微创外科技术在肝门部胆管癌根治术中的现状与思考[J].中华消化外科杂志, 2023, 22(7):848-852. DOI: 10.3760/cma.j.cn115610-20230612-00278.
[4]
中华医学会外科学分会胆道外科学组, 解放军全军肝胆外科专业委员会. 肝门部胆管癌诊断和治疗指南(2013版)[J].中华外科杂志, 2013, 51(10):865-871. DOI: 10.3760/cma.j.issn.0529-5815.2013.10.001.
[5]
LeeHY, KimSH, LeeJM, et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria[J]. Radiology, 2006, 239(1):113-121. DOI: 10.1148/radiol.2383050419.
[6]
TzedakisS, SindayigayaR, DhoteA, et al. Perihilar cholangiocarcinoma: what the radiologist needs to know[J]. Diagn Interv Imaging, 2022, 103(6):288-301. DOI: 10.1016/j.diii.2022.03.001.
[7]
CoelenR, RoosE, WiggersJK, et al. Endoscopic versus percutaneous biliary drainage in patients with resectable peri-hilar cholangiocarcinoma: a multicentre, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(10):681-690. DOI: 10.1016/S2468-1253(18)30234-6.
[8]
ParodiA, FisherD, GiovanniniM, et al. Endoscopic manage-ment of hilar cholangiocarcinoma[J]. Nat Rev Gastroenterol Hepatol, 2012, 9(2):105-112. DOI: 10.1038/nrgastro.2011.271.
[9]
FreesmeyerM, DrescherR, KühnelC, et al. Hepatobiliary excretion PET/CT with 68Ga-TAoS-DAZA to evaluate bile duct patency[J]. Clin Nucl Med, 2022, 47(1):59-60. DOI: 10.1097/RLU.0000000000003719.
[10]
中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专家工作组. 胆道恶性肿瘤全程规范化管理中国专家共识(2023)[J].中华外科杂志, 2024, 62(6):504-513. DOI: 10.3760/cma.j.cn112139-20240203-00062.
[11]
李斌, 姜小清. 肝门部胆管癌根治术关键技术标准及评价[J].中国实用外科杂志, 2024, 44(1):55-60. DOI: 10.19538/j.cjps.issn1005-2208.2024.01.08.
[12]
中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科医师委员会. 胆道镜临床应用专家共识(2018版)[J].中国实用外科杂志, 2018, 38(1):21-24. DOI: 10.19538/j.cjps.issn1005-2208.2018.01.02.
[13]
Ilyas SI, EatonJ, YangJD, et al. Emerging technologies for the diagnosis of perihilar cholangiocarcinoma[J]. Semin Liver Dis, 2018, 38(2):160-169. DOI: 10.1055/s-0038-1655775.
[14]
IlyasSI, KhanSA, HallemeierCL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2):95-111. DOI: 10.1038/nrclinonc.2017.157.
[15]
MalikowskiT, LevyMJ, GleesonFC, et al. Endoscopic ultrasound/fine needle aspiration is effective for lymph node staging in patients with cholangiocarcinoma[J]. Hepatology, 2020, 72(3):940-948. DOI: 10.1002/hep.31077.
[16]
郭鹏, 别平. 《胆道镜在肝胆管结石病诊断与治疗中的应用专家共识(2019版)》解读[J].临床肝胆病杂志, 2020, 36(1):57-58. DOI: 10.3969/j.issn.1001-5256.2020.01.012.
[17]
BukhariMA, Haito-ChavezY, NgamruengphongS, et al. Ren-dezvous biliary recanalization of complete biliary obstruction with direct peroral and percutaneous transhepatic cholangioscopy[J]. Gastroenterology, 2018, 154(1):23-25. DOI: 10.1053/j.gastro.2017.09.050.
[18]
张波, 姚怡, 张文刚, . 胆道镜直视系统在胆胰"超级微创理念"中的诊疗价值[J/CD].中华胃肠内镜电子杂志, 2023, 10(4):264-266. DOI: 10.3877/cma.j.issn.2095-7157.2023.04.006.
[19]
PereiraP, SantosS, MoraisR, et al. Role of peroral cholangioscopy for diagnosis and staging of biliary tumors[J]. Dig Dis, 2020, 38(5):431-440. DOI: 10.1159/000504910.
[20]
KawashimaH, OhnoE, IshikawaT, et al. Endoscopic mana-gement of perihilar cholangiocarcinoma[J]. Dig Endosc, 2022, 34(6):1147-1156. DOI: 10.1111/den.14317.
[21]
KuriharaT, YasudaI, IsayamaH, et al. Diagnostic and therapeutic single-operator cholangiopancreatoscopy in biliopancreatic diseases: prospective multicenter study in Japan[J]. World J Gastroenterol, 2016, 22(5):1891-1901. DOI: 10.3748/wjg.v22.i5.1891.
[22]
ChiangCH, ChenKC, DevereauxB, et al. Precise mapping of hilar cholangiocarcinoma with a skip lesion by SpyGlass cholangioscopy: a case report[J]. World J Gastrointest Surg, 2023, 15(5):965-971. DOI: 10.4240/wjgs.v15.i5.965.
[23]
DiliA, BertrandC. Laparoscopic ultrasonography as an alternative to intraoperative cholangiography during laparoscopic cholecystectomy[J]. World J Gastroenterol, 2017, 23(29):5438-5450. DOI: 10.3748/wjg.v23.i29.5438.
[24]
RussolilloN, BorelloA, LangellaS, et al. Comparison of lapa-roscopic ultrasound and liver-specific magnetic resonance imaging for staging colorectal liver metastases[J]. Surg Endosc, 2021, 35(7):3547-3553. DOI: 10.1007/s00464-020-07817-9.
[25]
中国肝胆外科术中超声学院. 术中超声在胆道外科的应用中国专家共识(2022版)[J].中华肝胆外科杂志, 2023, 29(1):5-14. DOI: 10.3760/cma.j.cn113884-20221215-00465.
[26]
王宏光, 王之浩. 腹腔镜解剖性肝段切除术中吲哚菁绿荧光染色方法选择和术中超声应用策略[J].中华消化外科杂志, 2024, 23(2):228-235. DOI: 10.3760/cma.j.cn115610-20231203-00231.
[27]
Montalvo-JavéEE, MendozaBarrera GE, ValderramaTreviño AI, et al. Absorbable bioprosthesis for the treatment of bile duct injury in an experimental model[J]. Int J Surg, 2015, 20:163-169. DOI: 10.1016/j.ijsu.2015.06.074.
[28]
KawakamiH, KuwataniM, AbeY, et al. A guidewire-assis-ted biopsy technique to assist advancement through a biliary stricture to perform selective mapping biopsy[J]. Endoscopy, 2015, 47(Suppl 1)UCTN:E217-E218. DOI: 10.1055/s-0034-1391827.
[29]
MatsumoriT, UzaN, ShiokawaM, et al. Mapping biopsy for bile duct cancer using a novel device delivery system[J]. Endoscopy, 2022, 54(5):E217-E219. DOI: 10.1055/a-1479-1969.
[30]
蒋青伟, 吴晰, 姚方, . 胆管癌和良性胆管狭窄的胆管腔内超声声像学特征比较[J].中华消化内镜杂志, 2019, 36(4):265-268. DOI: 10.3760/cma.j.issn.1007-5232.2019.04.009.
 
 
展开/关闭提纲
查看图表详情
回到顶部
放大字体
缩小字体
标签
关键词